SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders
NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Verve Therapeutics, Inc. (NASDAQ: VERV)'s sale to Eli Lilly and Company. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones. If you are a Verve shareholder, click here to learn more about your rights and options.
Sage Therapeutics, Inc. (NASDAQ: SAGE)'s sale to Supernus Pharmaceuticals, Inc. Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon achieving certain net sales and commercial milestones. If you are a Sage shareholder, click here to learn more about your legal rights and options.
Cantaloupe, Inc. (NASDAQ: CTLP)'s sale to 365 Retail Markets, LLC for $11.20 per share in cash. If you are a Cantaloupe shareholder, click here to learn more about your rights and options.
Volato Group, Inc. (NYSE: SOAR)'s merger with M2i Global, Inc. Upon completion of the proposed transaction, current Volato shareholders will own approximately 10% of the combined company. If you are a Volato shareholder, click here to learn more about your rights and options.
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:Halper Sadeh LLCDaniel Sadeh, Esq.Zachary Halper, Esq.One World Trade Center85th FloorNew York, NY 10007(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds
STATEN ISLAND, N.Y., June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a warrant inducement agreement (the "Letter Agreement") with a certain holder ("Holder") of existing warrants to purchase up to an aggregate of 4,445,435 shares of common stock (the "Existing Warrants") having exercise prices ranging from $3.25 to $3.26 per share, issued by the Company in July 2022 and May 2023, wherein the Holder agreed to exercise the Existing Warrants at a reduced exercise price of $0.675 per share, resulting in gross proceeds of approximately $2.67 million, before deducting offering fees and other expenses payable by the Company. In consideration for the exercise of the Existing Warrants for cash, the investors received 6,223,609 G-1 warrants (the "G-1 Warrants") and 2,667,261 G-2 warrants (the "G-2 Warrants) to purchase up to an aggregate of 8,890,870 shares of common stock (the "New Warrants"). The G-1 Warrants are exercisable immediately at an exercise price of $0.425 per common share and will expire five years from the issuance date. The G-2 Warrants are exercisable upon shareholder approval at an exercise price of $0.425 per common share and will expire five years from the issuance date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective resale registration statements on Form S-1 (File Nos. 333-267412 and 333-273015). The transaction is expected to close no later than June 20, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the exercise for working capital and general corporate purposes. The New Warrants are being issued in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such New Warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the New Warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Ibezapolstat Ibezapolstat is the Company's lead antibiotic candidate advancing to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillinresistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, the timing and completion of the offering; the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law. Investor Contact: Acurx Pharmaceuticals, Inc. David P. Luci, President & Chief Executive Officer Tel: 917-533-1469 Email: davidluci@ View original content: SOURCE Acurx Pharmaceuticals, Inc. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Should You Buy Nvidia While It's Below $150?
Nvidia, after falling below $100 earlier this year, now is a few dollars away from $150. The top AI company has benefited from surging AI demand, and this momentum could continue. 10 stocks we like better than Nvidia › The earlier part of the year wasn't easy for market superstar Nvidia (NASDAQ: NVDA). The stock slumped for a few reasons -- from worries about U.S. export controls on artificial intelligence (AI) chips for the Chinese market and a U.S. plan to set tariffs on imports, to concerns about technology spending. Each of these areas represents a risk for the leading AI chip designer, and that kept the stock trading well below $150. In fact, at its lowest, Nvidia slipped to less than $100 earlier in the year. But, in recent weeks, the stock has rebounded, erasing losses for the year and showing signs of renewed momentum -- and it's now just a few dollars away from $150. Though the export control issue remains, the other headwinds have eased. Technology companies in recent earnings reports say they continue to pour investment into AI, a good sign for Nvidia. As for the tariffs, President Donald Trump has signed initial agreements with the U.K. and China that offer investors optimism the duties may not dramatically impact corporate earnings. Considering all of this, should you get in on Nvidia while it's below $150? Nvidia soared into the spotlight in recent years thanks to one wise move: the decision to focus on the AI market before everyone was talking about AI. Nvidia's graphics processing units (GPUs) originally served the gaming market, but more than a decade ago, the company saw the potential of AI and shifted focus. From that point on, "every chip that we made was focused on artificial intelligence," CEO Jensen Huang told CNBC in a 2023 interview. This has been a winning bet for Nvidia because in recent years, data center revenue -- which encompasses AI products and services -- has skyrocketed. In the latest fiscal year, revenue surged in the triple digits to a record $130 billion. But Nvidia isn't only growing revenue. The company also has significantly increased net income thanks to its high profitability on sales -- gross margin has surpassed 70% in recent quarters, and Nvidia aims for that to continue. (In the most recent quarter, Nvidia booked a charge for lost sales in China linked to export restrictions, pushing gross margin to about 60% -- but excluding this, the margin figure once again surpassed 70%.) Speaking of China, this is one area that investors have worried about, since the region did account for 13% of sales as recently as last year. But it's important to keep in mind that Nvidia generates the lion's share of its revenue from U.S. customers, so even though the China situation may weigh on growth, it's unlikely to considerably slow down this AI giant. Last year, Nvidia brought in more than $61 billion in revenue from the U.S., and demand continues to grow as more and more customers seek computing power for AI inference -- an area of expertise for Nvidia's new Blackwell architecture and chip. Rivals, of course, also represent a headwind. For example, Advanced Micro Devices recently launched MI350, a family of chips that aims to challenge Nvidia's Blackwell. But even with a high-performing GPU, it will be difficult to unseat Nvidia, especially since this market leader innovates on an annual basis -- this makes it particularly tough for a competitor to make a significant mark on Nvidia's market share. And, considering demand ahead, there's likely plenty of room for Nvidia and a competitor like AMD to each generate major growth in this market. Today, the AI infrastructure buildout continues in a big way, and at the same time, new phases of AI growth -- such as the use of AI agents to apply AI to real-world problems -- are just beginning. Nvidia has wisely built an entire portfolio of AI products and services so that it can benefit from every stage of AI development and use. All of this means that, even though Nvidia has delivered double-digit growth in recent times, this growth story is likely to continue well into the future. Should you buy Nvidia while it's below $150? Even if you buy Nvidia once it passes that level, if you hold on for the long term, you could be setting yourself up for significant gains. So, you don't have to rush to get in on the stock right this second. But Nvidia makes a compelling buy now considering its current valuation -- trading at 33 times forward earnings estimates, down from more than 50 earlier in the year. While Nvidia is trading around these levels -- and under $150 -- it makes an excellent addition to your AI portfolio. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices and Nvidia. The Motley Fool has a disclosure policy. Should You Buy Nvidia While It's Below $150? was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Latest News In Energy Transition - CleanChoice Energy Expands Renewable Portfolio With New Solar Projects
CleanChoice Energy is broadening its renewable energy portfolio with the acquisition of two solar projects in New York State, aimed at generating a combined 54.2 MW of clean electricity. These projects, situated in Washington and Rensselaer Counties, were selected by the New York State Energy Research and Development Authority as part of efforts to meet the state's goal of 70% clean electricity by 2030. This expansion marks a significant stride in CleanChoice's strategy to bolster its solar generation capacity and strengthen community connections to locally-produced clean energy. As national and regional electricity grids face rising demand and consumer interest in sustainable energy solutions, initiatives like these underscore the ongoing transition towards renewable energy sources. In other trading, was a notable mover up 11% and ending the day at $49.79. At the same time, lagged, down 6.1% to end the day at $117.13. On Tuesday, the company declared a regular quarterly cash dividend of $0.55 per share. Fluor Corporation's strategic shift towards high-growth markets may lead to net margin improvements. Explore Fluor's transformative strategy and its potential impact on earnings here. Don't miss the Market Insights article "Opportunities In The Turbulent Transition To Greener Energy," which explores current renewable stock struggles and emerging nuclear options; read it now before market shifts. finished trading at $167.86 up 2%. settled at $144.78 up 1%. settled at $326.43 up 0.1%. Click through to start exploring the rest of the 153 Energy Transition Stocks including Jiangsu Financial Leasing, Dubai Electricity and Water Authority (PJSC) and Hindustan Zinc now. Interested In Other Possibilities? These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sources: Simply Wall St "CleanChoice Energy Expands Footprint with its First Two Solar Projects in New York State" from CleanChoice Energy on GlobeNewswire (published 11 June 2025) Companies discussed in this article include NYSE:FLR NasdaqGS:FSLR NYSE:CVX NasdaqGS:TSLA and NYSE:NUE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
